NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News $55.50 +2.40 (+4.52%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$52.43▼$55.5250-Day Range$50.00▼$61.2652-Week Range$6.93▼$63.40Volume298,186 shsAverage Volume457,753 shsMarket Capitalization$3.47 billionP/E RatioN/ADividend YieldN/APrice Target$58.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MoonLake Immunotherapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside5.9% Upside$58.80 Price TargetShort InterestHealthy16.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 3 Articles This WeekInsider TradingAcquiring Shares$40 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.93) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector825th out of 964 stocksBiotechnology Industry23rd out of 29 stocks 2.4 Analyst's Opinion Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $58.80, MoonLake Immunotherapeutics has a forecasted upside of 5.9% from its current price of $55.50.Amount of Analyst CoverageMoonLake Immunotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted16.84% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently decreased by 10.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLTX. Previous Next 3.0 News and Social Media Coverage News SentimentMoonLake Immunotherapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MoonLake Immunotherapeutics this week, compared to 2 articles on an average week.Search Interest14 people have searched for MLTX on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.MarketBeat Follows5 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.27% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($0.93) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -53.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -53.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 42.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MoonLake Immunotherapeutics (NASDAQ:MLTX) StockMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.Read More MLTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLTX Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 19, 2023 | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)September 27, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 18, 2023 | finance.yahoo.comThese 8 Stocks Are Outperforming Nvidia In 2023September 17, 2023 | msn.comAcelyrin, MoonLake rivalry heats up as both chase blockbuster PsA marketSeptember 17, 2023 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Downgraded to "Neutral" at Bryan, Garnier & CoSeptember 15, 2023 | msn.comCantor Fitzgerald Reiterates MoonLake Immunotherapeutics - (MLTX) Overweight RecommendationSeptember 14, 2023 | wsj.comMoonLake ImmunotherapeuticsSeptember 27, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 13, 2023 | msn.comNeedham Reiterates MoonLake Immunotherapeutics - (MLTX) Buy RecommendationSeptember 12, 2023 | finance.yahoo.comThe Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10%September 12, 2023 | fool.comWhy Shares of MoonLake Immunotherapeutics Are Rising TuesdaySeptember 12, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), InflaRx (IFRX)September 6, 2023 | finance.yahoo.comMoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11August 31, 2023 | msn.comNeedham Initiates Coverage of MoonLake Immunotherapeutics - (MLTX) with Buy RecommendationAugust 28, 2023 | msn.comAnchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)August 14, 2023 | msn.comWedbush Reiterates MoonLake Immunotherapeutics - (MLTX) Outperform RecommendationAugust 13, 2023 | fool.comMoonLake Immunotherapeutics (NASDAQ: MLTX)August 11, 2023 | markets.businessinsider.comJefferies Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Ligand Pharma (LGND) and Immunocore Holdings (IMCR)August 11, 2023 | markets.businessinsider.comMoonLake Immunotherapeutics (MLTX) Receives a Buy from LifeSci CapitalAugust 10, 2023 | finanznachrichten.deMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 10, 2023 | finance.yahoo.comMoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 2, 2023 | msn.comMoonLake Immunotherapeutics - (MLTX) Price Target Increased by 11.60% to 61.81August 1, 2023 | msn.comWedbush Maintains MoonLake Immunotherapeutics - (MLTX) Outperform RecommendationJuly 28, 2023 | markets.businessinsider.comWedbush Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)July 25, 2023 | finance.yahoo.comMoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readoutsSee More Headlines Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MLTX CUSIPN/A CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Forecast$58.80 High Stock Price Forecast$86.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+5.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.18% Return on Assets-22.26% Debt Debt-to-Equity RatioN/A Current Ratio70.97 Quick Ratio70.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book42.69Miscellaneous Outstanding Shares62,446,000Free Float52,910,000Market Cap$3.47 billion OptionableNot Optionable Beta1.46 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Jorge Santos da Silva (Age 45)Co-Founder, CEO & Director Comp: $1.11MDr. Kristian Reich (Age 57)Co-Founder & Chief Scientific Officer Comp: $1.2MMr. Matthias Bodenstedt (Age 35)Chief Financial Officer Comp: $588.25kMr. Oliver DaltropChief Technical OfficerNicolas MosimannGen. CounselAnnett ZippelDirector of People & CultureMs. Nuala BrennanChief Clinical Devel. OfficerMore ExecutivesKey CompetitorsEvotecNASDAQ:EVOAxsome TherapeuticsNASDAQ:AXSMAmicus TherapeuticsNASDAQ:FOLDCorcept TherapeuticsNASDAQ:CORTImmunoGenNASDAQ:IMGNView All CompetitorsInsiders & InstitutionsNuveen Asset Management LLCBought 140,000 shares on 8/16/2023Ownership: 0.266%HighVista Strategies LLCBought 7,521 shares on 8/15/2023Ownership: 0.246%Hudson Bay Capital Management LPBought 60,000 shares on 8/15/2023Ownership: 0.114%Woodline Partners LPBought 49,479 shares on 8/15/2023Ownership: 0.094%Royal Bank of CanadaBought 19,540 shares on 8/15/2023Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions MLTX Stock - Frequently Asked Questions Should I buy or sell MoonLake Immunotherapeutics stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MLTX shares. View MLTX analyst ratings or view top-rated stocks. What is MoonLake Immunotherapeutics' stock price forecast for 2023? 10 Wall Street research analysts have issued 1 year target prices for MoonLake Immunotherapeutics' shares. Their MLTX share price forecasts range from $16.00 to $86.00. On average, they predict the company's stock price to reach $58.80 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price. View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts. How have MLTX shares performed in 2023? MoonLake Immunotherapeutics' stock was trading at $10.50 at the start of the year. Since then, MLTX stock has increased by 428.6% and is now trading at $55.50. View the best growth stocks for 2023 here. When is MoonLake Immunotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our MLTX earnings forecast. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. What ETFs hold MoonLake Immunotherapeutics' stock? ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA SmallCap Momentum ETF (DWAS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Harbor Health Care ETF (MEDI), First Trust IPOX Europe Equity Opportunities ETF (FPXE) and BlackRock Future Health ETF (BMED).Goldman Sachs Future Health Care Equity ETF (GDOC). What is MoonLake Immunotherapeutics' stock symbol? MoonLake Immunotherapeutics trades on the NASDAQ under the ticker symbol "MLTX." Who are MoonLake Immunotherapeutics' major shareholders? MoonLake Immunotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (15.45%), Citadel Advisors LLC (3.83%), Alliancebernstein L.P. (1.59%), Polar Capital Holdings Plc (1.40%), BlackRock Inc. (1.25%) and Banque Pictet & Cie SA (1.21%). View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MoonLake Immunotherapeutics' stock price today? One share of MLTX stock can currently be purchased for approximately $55.50. How much money does MoonLake Immunotherapeutics make? MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $3.47 billion. The company earns $-49,970,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. How can I contact MoonLake Immunotherapeutics? The official website for the company is www.moonlaketx.com. The company can be reached via phone at 41-41-510-8022 or via email at ir@moonlaketx.com. This page (NASDAQ:MLTX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.